Overview

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital of Zhengzhou University

Treatments:

130-nm albumin-bound paclitaxel
anlotinib
camrelizumab
S 1 (combination)